Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.15 (
renin
)
35,795
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In normoalbuminuric patients with insulin-dependent diabetes mellitus, plasma
atrial natriuretic factor
(
ANF
), cyclic GMP and active
renin
and the renal clearances of [99Tcm]-diethylenetriaminepentaacetic acid (DTPA) lithium and sodium were studied on a hyperglycaemia day and a euglycaemia day. Baseline euglycaemia was achieved by an overnight variable insulin infusion, which during study days was fixed at the rate necessary to maintain euglycaemia in the morning. After a baseline euglycaemic clearance period of 90 min, measurements were repeated in a new 90-min period beginning 150 min later. On the hyperglycaemia day i.v. infusion of 20% glucose was started at the end of the euglycaemic baseline period, increasing blood glucose (5.3 +/- 1.3 vs 12.1 +/- 1.2 mmol l-1, p less than 0.01). On the euglycaemia day blood glucose declined (5.1 +/- 1.0 vs 4.2 +/- 1.0 mmol l-1, p less than 0.02). Glomerular filtration rate (GFR) was unchanged by acute hyperglycaemia (127 +/- 16 vs 129 +/- 24 ml min-1, NS), but nearly normalized during maintained euglycaemia on the euglycaemia day (124 +/- 17 vs 105 +/- 16 ml min-1, p less than 0.01). When comparing the hyperglycaemic study period with the similarly timed period on the euglycaemia day, GFR was elevated by hyperglycaemia (129 +/- 24 vs 105 +/- 16 ml min-1, p less than 0.01), while the renal clearances of lithium and sodium were similar. Consequently, the calculated absolute proximal reabsorption rate of sodium and water was elevated during hyperglycaemia. Hyperglycaemia reduced the slight decline in plasma concentrations of
ANF
and cyclic GMP observed on the euglycaemia day. Active
renin
, glucagon and plasma osmolality were unchanged. In conclusion, marked changes in glomerular filtration rate are induced by changes in blood glucose concentration, but the effect is delayed and thus not directly related to renal tubular transport of glucose. Hyperglycaemia does not affect renal clearances of lithium and sodium, while proximal tubular reabsorption is markedly stimulated. These changes are not related to changes in
ANF
,
renin
, glucagon or plasma osmolality.
...
PMID:Effects of hyperglycaemia on kidney function, atrial natriuretic factor and plasma renin in patients with insulin-dependent diabetes mellitus. 166 32
Five weeks of high (8%) sodium intake, resulting in a decline of plasma
atrial natriuretic factor
(
ANF
) in normotensive Wistar-Kyoto (WKY) and Wistar rats, did not affect plasma
ANF
in spontaneously hypertensive rats (SHR) which became severely hypertensive. Regardless of salt consumption, SHR presented more pronounced glomerular particulate guanylate cyclase activation after large
ANF
doses in vitro than normotensive rats. In response to salt loading, plasma
renin
activity (PRA) and plasma aldosterone unexpectedly increased in SHR, in contrast to their decrease in the normotensive strains. Thus, SHR fail to react to prolonged high-salt intake as do normotensive rats, i.e. by a fall in plasma
ANF
, PRA and plasma aldosterone, and have higher stimulated glomerular particulate guanylate cyclase activity. Thus,
ANF
and its target response in SHR, as well as the PRA-plasma aldosterone reaction to prolonged salt loading, are distinct from those in normotensive strains. Since the relatively increased
ANF
and its target action in SHR appear to be a reactive antihypertensive defense rather than a primary event, systems other than
ANF
probably play an important role in the high salt-induced accelerated hypertension of SHR.
...
PMID:Distinct plasma atrial natriuretic factor, renin and aldosterone responses to prolonged high-salt intake in hypertensive and normotensive rats. 167 17
To examine how
atrial natriuretic factor
(
ANF
) inhibits
renin
release during renal sympathetic nerve stimulation, experiments were performed in barbiturate-anesthetized dogs. In five dogs, intravenous
ANF
infusion (50 ng.min-1.kg body wt-1) reduced
renin
release induced by renal nerve stimulation (1 Hz) from 16.8 +/- 8.4 to 3.5 +/- 2.1 micrograms angiotensin I (ANG I)/min. In two groups,
renin
release was raised by ureteral occlusion, which enhances the effects of beta-adrenoceptor stimulation and increased prostaglandin synthesis. During ureteral occlusion, intrarenal infusion of isoproterenol (0.2 micrograms.min-1.kg body wt-1) increased
renin
release in eight dogs to 82.6 +/- 10.9 micrograms ANG I/min, which was not significantly reduced by
ANF
infusion (81.1 +/- 10.1 micrograms ANG I/min). Similarly, intrarenal infusion of arachidonic acid (80 micrograms.min-1.kg body wt-1) during ureteral occlusion increased
renin
release in five dogs to 22.2 +/- 3.0 micrograms ANG I/min, which was not significantly reduced by
ANF
infusion (22.5 +/- 3.5 micrograms ANG I/min). Finally, in six dogs examined at free urine flow, intrarenal infusion of phenylephrine, an alpha-adrenergic agonist, raised
renin
release from 0.5 +/- 0.3 to 20.1 +/- 6.8 micrograms ANG I/min, which was reduced to 10.6 +/- 3.9 micrograms ANG I/min by intravenous
ANF
infusion (100 ng.min-1.kg body wt-1). These results indicate that
ANF
does not counteract stimulation of
renin
release by beta-adrenoceptors and prostaglandins but reduces nerve-stimulated
renin
release by opposing alpha-adrenoceptor activity.
...
PMID:Atrial natriuretic factor reduces renin release by opposing alpha-adrenoceptor activity. 167 82
The acute effects of i.v. somatostatin (250 mcg bolus followed by 250 mcg/h continuous infusion for two hours) on renal hemodynamics, renal electrolyte and water handling, and urinary excretion of catecholamines and prostaglandins, as well as on plasma concentrations of arginine vasopressin,
atrial natriuretic factor
, norepinephrine, epinephrine, dopamine, glucagon, and plasma
renin
activity were studied in seven normal subjects. Somatostatin decreased effective renal plasma flow and glomerular filtration rate, osmotic and free water clearances, urine volume, and sodium and potassium excretion, while urinary osmolality, fractional excretion of sodium, and phosphate excretion increased significantly. Plasma concentrations of arginine vasopressin,
atrial natriuretic factor
, norepinephrine, epinephrine, and dopamine remained unchanged, while plasma
renin
activity (3.0 +/- 0.25 vs 2.4 +/- 0.2 ng AngI/ml/h; p less than 0.01) and glucagon levels (40 +/- 11 vs 20 +/- 16 pg/ml; p less than 0.01) decreased. Urinary excretion of norepinephrine, epinephrine, dopamine, PGE2, and PGF2 alpha was suppressed under somatostatin. A significant positive correlation was found between urinary dopamine and sodium excretion (r = 0.7; p less than 0.001) and urinary prostaglandin E2 and glomerular filtration (r = 0.52; p less than 0.01). Without accompanying changes in plasma osmolality and vasopressin concentration significant antidiuresis occurred, suggesting a direct tubular effect of somatostatin. However, the hormone-induced changes are due mainly to the decrease in renal plasma flow. The results demonstrate that somatostatin at supraphysiological doses exerts significant effects on the kidney.
...
PMID:Effect of somatostatin on kidney function and vasoactive hormone systems in health subjects. 168 Nov 32
Present views on the biological significance of
atrial natriuretic factor
(
ANF
) relate this polypeptide hormone to the regulation of blood pressure and volume through its modulating effects on renal function, on blood vessel tone and permeability, and on the
renin
-angiotensin-aldosterone system. Although very important advances in the understanding of
ANF
have been made over the decade since its discovery, some fundamental facts about
ANF
biosynthesis and release remain to be elucidated. Stretch-induced enhancement of
ANF
release appears as the most significant mechanism underlying the endocrine response of the atria to acute volume load. This response decays over a period of minutes, indicating that chronic stimulation of
ANF
release involves mechanisms different from, or in addition to, those acting during acute stretch-stimulated release. In neither acute nor chronic conditions are the cellular or molecular mechanisms underlying
ANF
release understood. To better understand long-term stimulation of
ANF
release, we have conducted extensive in vitro testing of several hormones and neurotransmitters to determine their ability to modify
ANF
release. From these studies, clear-cut evidence of
ANF
stimulation was obtained with the vasopressor peptide endothelin. Investigations on the cell and molecular biology of cardiac muscle development and hypertrophy have shown that
ANF
is involved in cardiac growth. The role played by
ANF
in these processes is now being determined, but this is one line of evidence that suggests that this hormone, together with other natriuretic peptides, may have autocrine or paracrine functions.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:A decade of atrial natriuretic factor research. 168 94
Ibopamine (IP) is a novel dopamine analogue for which beneficial effects have been shown in chronic heart failure. Hemodynamic effects of the substance include an increase in cardiac output and a decrease in the peripheral resistance. Aside from these hemodynamic effects, changes in renal (increased diuresis) and neurohumoral parameters (decreased plasma
renin
activity, aldosterone, norepinephrine, increased
ANF
and cGMP) have been found. The renal effects may originate from three independent mechanisms: 1) direct impact of improved hemodynamic parameters on the renal perfusion; 2) the improved cardiac performance results in a reduction of compensatory hormonal adaptations, such as the activation of the
renin
-angiotensin-aldosterone-axis or the sympathetic system; 3) direct effects on the intrarenal hemodynamic and glomerular/tubular functions induced by stimulation of renal dopaminergic receptors. The continued decrease of the plasma
renin
activity by 35% results in a reduction of the plasma levels of angiotensin II and aldosterone. Additionally, an increase in plasma
atrial natriuretic factor
(
ANF
) and its second messenger cyclic guanosine monophosphate (cGMP) was observed after ibopamine, which could contribute to the diuretic action of the drug. These findings underline the importance of extrarenal effects of a drug in the treatment of heart failure, this may essentially contribute to the improvement of cardiac performance, independent of positive inotropy.
...
PMID:[Ibopamine--acute hemodynamic, renal and neurohumoral effects]. 168 94
In the second part of this review concerning adrenocortical growth factors, the following stimulatory agents are included:
renin
, angiotensin II,
atrial natriuretic factor
(
ANF
), prostaglandins--in vivo, fibroblast growth factor (FGF), epidermal growth factor (EGF), adrenal growth factor (AGF) and adrenergic innervation. Furthermore, some growth-inhibiting factors are discussed, as follows: prostaglandins--in vitro, somatostatin, melatonin and N-acetylserotonin.
...
PMID:[Factors stimulating and/or inhibiting the growth processes in the adrenal cortex. II. The role of the renin-angiotensin system, tissue growth factors, pineal indole amines and the nervous system]. 168 10
The effects of pretreatment with
atrial natriuretic factor
(
ANF
) on the pressor responsiveness to injections of angiotensin II (ANGII), arginine vasopressin (AVP), and norepinephrine (NE), as well as the effect of pretreatment with ANGII on the hypotensive responses to
ANF
injection were studied in conscious sheep. The hemodynamic effects of
ANF
infusion (100 micrograms/h for 60 min) were also examined in animals pretreated with the angiotensin-converting enzyme (ACE) inhibitor, captopril. Infusion of
ANF
attenuated the pressor responsiveness to exogenous AII and NE, but caused no significant change in the blood pressure increases produced by vasopressin. In contrast, infusion of AII had no effect on the immediate hypotensive response to
ANF
injection. Infusion of
ANF
for 60 min produced similar hemodynamic actions in sheep during ACE inhibition as compared with the responses observed in normal sheep, although the reduction in cardiac output and increase in calculated total peripheral resistance was attenuated. Infusion of captopril increased plasma concentration of
renin
(PRC), and infusion of
ANF
produced no further change in PRC. In conclusion, the short-term cardiovascular responses to
ANF
infusion in conscious sheep are not mediated solely by inhibition of the
renin
-angiotensin system. However,
ANF
attenuates the pressor actions of pharmacologic doses of exogenous ANGII and NE. In contrast, the vasodepressor response to exogenous
ANF
injection was not altered in animals receiving ANGII infusion. This study suggests that
ANF
may be important in regulating the effects of endogenous vasoconstrictor hormones on blood pressure (BP).
...
PMID:Effects of atrial natriuretic factor on pressor responsiveness to angiotensin II, norepinephrine, and vasopressin in conscious sheep. 168 75
Atrial natriuretic peptide
(hANP 4-28) was infused for 1 h (0.3 microgram/kg/min) in 11 normal awake dogs and seven awake dogs with chronic left ventricular dysfunction, induced 16 weeks earlier by repetitive DC shock. The responses were similar in the two groups and included decreases in arterial pressure (107-99 mm Hg), heart rate (83-72 beats/min), and cardiac output (3.6-2.8 L/min), without changes in right or left ventricular filling pressures. Systemic vascular resistance (SVR) tended to rise during the infusion and was significantly increased (2,847-3,442 dyn s cm-5, p less than .05) during the postinfusion recovery period. Regional blood flows (microspheres) during infusion revealed a decrease in skin and splanchnic flow. Despite the apparent vasoconstrictor effect, plasma norepinephrine (PNE),
renin
activity (PRA), and arginine vasopressin (AVP) levels all fell during ANP infusion. These data suggest that ANP exerts a cardioinhibitory effect, possibly similar to that of arginine vasopressin (AVP), and that the net systemic vasoconstrictor effect of ANP in these dogs is mediated by a complex interrelationship between direct vascular effects, neurohormonal inhibition, and central reflex activation.
...
PMID:Cardiovascular and neurohormonal effects of atrial natriuretic peptide in conscious dogs with and without chronic left ventricular dysfunction. 169 88
Small-volume resuscitation with hypertonic saline in combination with dextran appears to be very successful in experimental animals, where better results are achieved than in animals treated with a traditional infusion regime. This effect is apparently related to improved organ blood flow due to reflex vasodilatation. This reflex is based on the arrival of hypertonic solution in the pulmonary circulation. The expansion of intravascular volume would seem to be of secondary importance.
Atrial natriuretic peptide
(
ANP
) is released from secretory granules located in atrial cardiocytes. Atrial distention appears to be the predominant stimulus triggering
ANP
production. In addition to the natriuretic and diuretic effects,
ANP
leads to vasodilation, especially when vascular tone is elevated; the sympathetic reflex seems to be attenuated. Cyclic Guanosine Monophosphate (cGMP) is an intracellular messenger and is partly released by
ANP
in the membrane-bound form. Renin excretion is highly influenced by
ANP
. The object of this study was to evaluate the influence of a hypertonic solution on this hormonal regulatory system. METHOD. This study compared a hypertonic sodium chloride solution (7.5%) in combination with hydroxyethyl starch (6%) (HH) to Ringer's lactate (RL). Six healthy volunteers received 4 ml/kg HH and 1 week later 500 ml RL. The infusion was administered in 20 minutes via a central venous catheter 70 cm in length. Blood pressure, heart rate, hemoglobin (Hb), hematocrit (Hk), colloid osmotic pressure (COP), sodium (Na+), chloride (Cl-), and plasma osmolarity were measured before starting and 5 and 30 min following infusion. At the same times
ANP
, cGMP, and plasma
renin
were also determined. RESULTS. Both groups showed no change in blood pressure or heart rate. The decrease of Hb, Hk, and COP in the HH and RL groups indicated the expansion of circulating plasma volume. HH infusion caused significant increases in
ANP
and cGMP, whereas plasma
renin
declined significantly. After RL infusion,
ANP
and
renin
values were very similar to the HH group except in one volunteer, who showed an extreme increase in
ANP
(760 pg/ml) 5 min after HH infusion. cGMP did not increase significantly in the RL group. On comparison of the two groups, only a significant difference in plasma osmolarity and in sodium and chloride levels was noted. CONCLUSION. We found that hypertonic NaCl (7.5%) with HH was well tolerated. Release of
ANP
and cGMP after HH infusion in healthy volunteers was not as high as expected, and the vasodilatory effect of hypertonic solutions was not explained by
ANP
or cGMP release in this investigation.
...
PMID:[Plasma levels of atrial natriuretic peptide, cyclic guanosine monophosphate and renin following 7.5% NaCl + 6% hydroxyethyl starch or Ringer's lactate. A comparative study of 6 normal subjects]. 170 29
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>